Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017

Home/Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017

Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017

Clinical Trials, Pharma & Healthcare

Publication ID:

GDA03171317

Publication Date:

March 31, 2017

Pages:

Publisher:

GlobalData

Region:

Global

$2,500.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, “Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017" provides an overview of Epidermolysis Bullosa clinical trials scenario. This report provides top line data relating to the clinical trials on Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Epidermolysis Bullosa Therapeutics Clinical Trials 23
Prominent Drugs 24
Latest Clinical Trials News on Epidermolysis Bullosa 25
Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex 25
Mar 06, 2017: Amryt Pharma Announces AP101 trial discussions completed with FDA & EMA 25
Feb 27, 2017: RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S. 25
Clinical Trial Profile Snapshots 27
Appendix 64
Abbreviations 64
Definitions 64
Research Methodology 65
Secondary Research 65
About GlobalData 66
Contact Us 66
Source 67

List of Tables
List of Tables
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region, 2017* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2017* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase, 2017* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 17
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2017* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2017* 19
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 20
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 22
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 23
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 24

List of Figures
List of Figures
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 12
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2017* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase (%), 2017* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 17
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2017* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2017* 19
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 20
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 22
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 23
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 24
GlobalData Methodology 65

Companies Covered

Amicus Therapeutics Inc
Amryt Pharma plc
WAVE Life Sciences Ltd
Fibrocell Science Inc
DEBRA International
Centre Hospitalier Universitaire de Nice
Castle Creek Pharmaceuticals LLC
Abeona Therapeutics Inc
Berg LLC
Anterogen Co Ltd

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".